Skip to main content
Erschienen in: Cancer Causes & Control 4/2010

01.04.2010 | Brief report

The impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25-hydroxyvitamin D concentrations

verfasst von: Chu-Ling Yu, Roni T. Falk, Michael G. Kimlin, Preetha Rajaraman, Alice J. Sigurdson, Ronald L. Horst, Louis M. Cosentino, Martha S. Linet, D. Michal Freedman

Erschienen in: Cancer Causes & Control | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Studies have examined the associations between cancers and circulating 25-hydroxyvitamin D [25(OH)D], but little is known about the impact of different laboratory practices on 25(OH)D concentrations. We examined the potential impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25(OH)D concentrations. Blood samples from 20 healthy volunteers underwent alternative laboratory procedures: four centrifuging times (2, 24, 72, and 96 h after blood draw); three types of collection tubes (red top serum tube, two different plasma anticoagulant tubes containing heparin or EDTA); and two types of assays (DiaSorin radioimmunoassay [RIA] and chemiluminescence immunoassay [CLIA/LIAISON®]). Log-transformed 25(OH)D concentrations were analyzed using the generalized estimating equations (GEE) linear regression models. We found no difference in 25(OH)D concentrations by centrifuging times or type of assay. There was some indication of a difference in 25(OH)D concentrations by tube type in CLIA/LIAISON®-assayed samples, with concentrations in heparinized plasma (geometric mean, 16.1 ng ml−1) higher than those in serum (geometric mean, 15.3 ng ml−1) (p = 0.01), but the difference was significant only after substantial centrifuging delays (96 h). Our study suggests no necessity for requiring immediate processing of blood samples after collection or for the choice of a tube type or assay.
Literatur
1.
Zurück zum Zitat Bertone-Johnson ER, Chen WY, Holick MF et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991–1997CrossRefPubMed Bertone-Johnson ER, Chen WY, Holick MF et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991–1997CrossRefPubMed
2.
Zurück zum Zitat Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95CrossRefPubMed Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95CrossRefPubMed
3.
Zurück zum Zitat Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88CrossRefPubMed Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88CrossRefPubMed
4.
Zurück zum Zitat Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef
5.
Zurück zum Zitat Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796–804CrossRefPubMed Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796–804CrossRefPubMed
6.
Zurück zum Zitat Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16:2784–2786CrossRefPubMed Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16:2784–2786CrossRefPubMed
7.
Zurück zum Zitat Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602CrossRefPubMed Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602CrossRefPubMed
8.
Zurück zum Zitat Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:783–788CrossRefPubMed Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:783–788CrossRefPubMed
9.
Zurück zum Zitat Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265CrossRefPubMed Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265CrossRefPubMed
10.
Zurück zum Zitat Landi MT, Caporaso N (1997) Sample collection, processing and storage. IARC Sci Publ 142:223–236PubMed Landi MT, Caporaso N (1997) Sample collection, processing and storage. IARC Sci Publ 142:223–236PubMed
11.
Zurück zum Zitat Tworoger SS, Hankinson SE (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 15:1578–1581CrossRefPubMed Tworoger SS, Hankinson SE (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 15:1578–1581CrossRefPubMed
12.
Zurück zum Zitat Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–1808CrossRefPubMed Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–1808CrossRefPubMed
13.
Zurück zum Zitat Hollis BW, Horst RL (2007) The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol 103:473–476CrossRefPubMed Hollis BW, Horst RL (2007) The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol 103:473–476CrossRefPubMed
14.
Zurück zum Zitat Ersfeld DL, Rao DS, Body JJ et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37:867–874CrossRefPubMed Ersfeld DL, Rao DS, Body JJ et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37:867–874CrossRefPubMed
15.
Zurück zum Zitat Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529–533PubMed Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529–533PubMed
16.
Zurück zum Zitat Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130CrossRefPubMed Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130CrossRefPubMed
18.
Zurück zum Zitat Lissner D, Mason RS, Posen S (1981) Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 27:773–774PubMed Lissner D, Mason RS, Posen S (1981) Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 27:773–774PubMed
19.
Zurück zum Zitat Mason RS, Posen S (1977) Some problems associated with assay of 25-hydroxycalciferol in human serum. Clin Chem 23:806–810PubMed Mason RS, Posen S (1977) Some problems associated with assay of 25-hydroxycalciferol in human serum. Clin Chem 23:806–810PubMed
20.
Zurück zum Zitat Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed
21.
Zurück zum Zitat Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42:1549–1556CrossRefPubMed Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42:1549–1556CrossRefPubMed
22.
Zurück zum Zitat Heaney RP (2005) The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97:13–19CrossRefPubMed Heaney RP (2005) The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97:13–19CrossRefPubMed
Metadaten
Titel
The impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25-hydroxyvitamin D concentrations
verfasst von
Chu-Ling Yu
Roni T. Falk
Michael G. Kimlin
Preetha Rajaraman
Alice J. Sigurdson
Ronald L. Horst
Louis M. Cosentino
Martha S. Linet
D. Michal Freedman
Publikationsdatum
01.04.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 4/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9485-x

Weitere Artikel der Ausgabe 4/2010

Cancer Causes & Control 4/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.